{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:27:16Z","timestamp":1792099636444,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Shire Human Genetic Therapies, Inc"},{"name":"Shire Human Genetic Therapies"},{"DOI":"10.13039\/100015362","name":"Amicus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shire Human Genetic Therapies"},{"name":"Shire Human Genetic Therapies"},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ymgme.2019.07.012","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T19:38:59Z","timestamp":1563997139000},"page":"150-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype"],"prefix":"10.1016","volume":"129","author":[{"given":"Olga","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Miltenberger-Miltenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Reim\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f3nia","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dami\u00e3o","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.07.012_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000455117","article-title":"Mild left ventricular hypertrophy unravels a novel nonsense mutation of the GLA gene associated with the classical phenotype of Fabry disease","volume":"137","author":"Azevedo","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.ymgme.2019.07.012_bb0025","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","article-title":"Prevalence of uncontrolled hypertension in patients with Fabry disease","volume":"19","author":"Kleinert","year":"2006","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant \u03b1-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0035","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0040","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","article-title":"The pulvinar sign: frequency and clinical correlations in Fabry disease","volume":"255","author":"Burlina","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/jhg.2010.58","article-title":"Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns","volume":"55","author":"Lee","year":"2010","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0050","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2350-11-19","article-title":"Frequency of Fabry disease in male and female haemodialysis patients in Spain","volume":"11","author":"Gaspar","year":"2010","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","article-title":"Detection of alpha-galactosidase A mutations causing Fabry disease by denaturing high performance liquid chromatography","volume":"25","author":"Shabbeer","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry\u2019s disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2019.07.012_bb0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","article-title":"Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"515","author":"Mills","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0075","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0080","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2019.07.012_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","article-title":"Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group","volume":"34","author":"Gal","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10545-013-9659-2","article-title":"Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS)","volume":"37","author":"Palecek","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0110","series-title":"Um Olhar Sobre os Registos Paroquiais de S\u00e3o Torcato \u2013 Uma Cr\u00edtica de Fonte","first-page":"213","volume":"vol. VIII","author":"Faria","year":"2007"},{"key":"10.1016\/j.ymgme.2019.07.012_bb0115","series-title":"Actas Do IV Congresso Hist\u00f3rico de Guimar\u00e3es \u2013 Do Absolutismo Ao Liberalismo","first-page":"193","article-title":"Pobreza na sucess\u00e3o das gera\u00e7\u00f5es, continuidade e rupturas em Guimar\u00e3es e seu termo nos s\u00e9culos XVII a XVIII","volume":"VI","author":"Faria","year":"2009"},{"key":"10.1016\/j.ymgme.2019.07.012_bb0120","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.07.012_bb0130","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0135","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/clc.22047","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"35","author":"Acharya","year":"2012","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0145","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-017-0127-2","article-title":"Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease","author":"Alharbi","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0150","doi-asserted-by":"crossref","first-page":"c35","DOI":"10.1159\/000324218","article-title":"Prevalence of chronic kidney disease and associated risk factors, and risk of end-stage renal disease: data from the PREVADIAB study","volume":"119","author":"Vinhas","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ymgme.2019.07.012_bb0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1468-1331.2010.03155.x","article-title":"Neuropsychiatric symptoms and brain structural alterations in Fabry disease","volume":"18","author":"Schermuly","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0160","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry\u2019s disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0165","first-page":"17","article-title":"Carpal tunnel syndrome in Fabry disease","volume":"2","author":"Ghali","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0170","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.07.012_bb0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Auray-Blais","year":"2017","journal-title":"Clin. Chim. Acta"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219304007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219304007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:24:28Z","timestamp":1761089068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719219304007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1096719219304007"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.07.012","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}